RNA Vaccines Pipeline Analysis Market: By Clinical Trial Phase (Pre-clinical Phase, Phase-I, Phase-II, Phase-III), By Application (Cancer, Renal Disorders, Cardiovascular Disorders, Metabolic Disorders, Infectious Diseases, Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

RNA Vaccines Pipeline Analysis Market size was valued at USD 35.43 billion in 2022 and is expected to reach USD 57.89 billion by 2028, at a significant CAGR of 12.2% from 2023-2029. Due to increase in prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries, rise in funding for the development of RNA vaccines from public and private sectors, promising pipeline drugs, and wide range of applications with RNA vaccines are the major factors that are driving the growth of the global RNA vaccines market over the forecast timeframe. The report studies global RNA vaccines dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global RNA vaccines market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global RNA vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global RNA vaccines market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA vaccines products.

Global Rna Vaccines Pipeline Analysis Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.20%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
RNA Vaccines Pipeline Analysis Market

Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA vaccines market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi vaccines, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA vaccines market over the forecast years.

Key Features of the Reports

  • Global RNA vaccines market expanding at significant CAGR over 2022 to 2028 owing to increase in the prevalence of cancer and other chronic diseases
  • Based on application, cancer segment accounted for larger market revenue share in 2021 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global RNA vaccines market

Global Rna Vaccines Pipeline Analysis Market Segmentation

By Clinical Trial Phase
  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III
By Application
  • Cancer
  • Renal Disorders
  • Cardiovascular Disorders
  • Metabolic Disorders
  • Infectious Diseases
  • Others
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The key segments covered in the RNA Vaccines Pipeline Analysis Market are technology, components, application, and end-users.

The RNA Vaccines Pipeline Analysis Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The RNA Vaccines Pipeline Analysis Market key players Moderna, Inc., CureVac AG, BioNTech AG, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, miRagen Vaccines, Inc., GeneOne Life Science

 

  1. Executive Summary
  2. Global RNA Vaccines Pipeline Analysis Introduction
    • Global RNA Vaccines Pipeline Analysis - Taxonomy
    • Global RNA Vaccines Pipeline Analysis -Definitions
      • Clinical Trial Phase
      • Application
  1. Global RNA Vaccines Pipeline Analysis Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global RNA Vaccines Pipeline Analysis Dynamic Factors - Impact Analysis
    • Global RNA Vaccines Pipeline Analysis - Competition Landscape
  2. Global RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029
    • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global RNA Vaccines Pipeline Analysis, By Clinical Trial Phase, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Pre-Clinical Phase
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-I
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-II
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase-III
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA Vaccines Pipeline Analysis Forecast, By Application, 2018-2022 and Forecast, 2023-2029
    • Cancer
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Renal Disorders
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cardiovascular Disorders
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Metabolic Disorders
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Infectious Diseases
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA Vaccines Pipeline Analysis Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Region, 2023-2029
  2. North America RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2023-2029
    • North America RNA Vaccines Pipeline Analysis Dynamics - Trends
  3. Europe RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2023-2029
    • Europe RNA Vaccines Pipeline Analysis Dynamics - Trends
  4. Asia-Pacific RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2023-2029
    • Asia-Pacific RNA Vaccines Pipeline Analysis Dynamics - Trends
  5. Latin America RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2023-2029
    • Latin America RNA Vaccines Pipeline Analysis Dynamics - Trends
  6. Middle East and Africa RNA Vaccines Pipeline Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    • Clinical Trial Phase Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Pre-Clinical Phase
      • Phase-I
      • Phase-II
      • Phase-III
    • Application Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Renal Disorders
      • Cardiovascular Disorders
      • Metabolic Disorders
      • Infectious Diseases
      • Others
    • Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA RNA Vaccines Pipeline Analysis - Opportunity Analysis Index, By Clinical Trial Phase, Application, and Country, 2023-2029
    • MEA RNA Vaccines Pipeline Analysis Dynamics - Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Clinical Trial Phase & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Moderna, Inc.
      • CureVac AG
      • BioNTech AG
      • Alnylam Pharmaceuticals, Inc.
      • Arbutus Biopharma Corporation
      • miRagen Therapeutics, Inc
      • GeneOne Life Sciences
  1. Research Methodology
  2. Key Assumptions and Acronyms
  • Moderna, Inc.
  • CureVac AG
  • BioNTech AG
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • miRagen Vaccines, Inc.
  • GeneOne Life Science

Adjacent Markets